Diabetes Obes Metab: Effects of empagliflozin on markers of hepatic steatosis and fibrosis and its association with cardiorenal outcomes

People with type 2 diabetes are prone to developing nonalcoholic fatty liver disease (NAFLD)
.

Type 2 diabetes further accelerates the progression of patients with NAFLD from simple steatosis to nonalcoholic steatohepatitis (NASH), fibrosis and cirrhosis

Diabetic nonalcoholic fatty liver vascular arrhythmia

This post-hoc study evaluated the effect of empagliflozin on the risk of nonalcoholic fatty liver disease (NAFLD)-associated steatosis and fibrosis, according to a research article published in Diabetes Obesity & Metabolism, a leading journal in the field of metabolic endocrine diseases.
and the relationship between risk categories and cardiorenal outcomes
.

Empagliflozin 10/25 mg/d or placebo was used to treat 7020 patients with type 2 diabetes and cardiovascular disease in the EMPA-REGOUTCOME trial
.

For the analysis, researchers calculated the Dallas Steatosis Index (DSI), Hepatic Steatosis Index (HSI), NAFLD Fibrosis Score (NFS), and Fibrosis-4 Score (FIB-4) to assess steatosis and fibrosis risk

At baseline, 73% and 84% of participants with DSI and HSI, respectively, were at high risk of steatosis, while 23% and 4% of participants with NFS and FIB-4, respectively, were at high risk of advanced fibrosis
.

The percentage of people at high steatosis risk who were treated with empagliflozin alone decreased slightly, while empagliflozin did not increase the percentage of people at high fibrosis risk over time compared with placebo

cardiovascular events

CONCLUSIONS: Empagliflozin can reduce steatosis but not fibrosis risk in patients with type 2 diabetes and cardiovascular disease
.

The improvement in cardiorenal outcomes and mortality associated with empagliflozin treatment appeared to be independent of steatosis and fibrosis risk

Empagliflozin reduces steatosis but not fibrosis risk in patients with type 2 diabetes and cardiovascular disease
.
The improvement in cardiorenal outcomes and mortality associated with empagliflozin treatment appeared to be independent of steatosis and fibrosis risk
.
Original source: Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomesLeave a comment here